Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

You Fei Guan, Chuanming Hao, Dae-Ryong Cha, Reena Rao, Wendell Lu, Donald E. Kohan, Mark A. Magnuson, Reyadh Redha, Yahua Zhang, Matthew D. Breyer

Research output: Contribution to journalArticle

470 Citations (Scopus)

Abstract

Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator- activated receptor-γ (PPARγ, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct-specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Ppargflox/flox mice. Deletion of collecting duct Pparg decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding the epithelial Na+ channel ENaCγ) expression through a PPARγ-dependent pathway. These studies identify Scnn1g as a PPARγ target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.

Original languageEnglish
Pages (from-to)861-866
Number of pages6
JournalNature Medicine
Volume11
Issue number8
DOIs
Publication statusPublished - 2005 Aug 1
Externally publishedYes

Fingerprint

Thiazolidinediones
Body fluids
Body Fluids
Ducts
Salts
Amiloride
Weight Gain
Epithelial Sodium Channels
Peroxisome Proliferator-Activated Receptors
Body Water
Nephrons
Aldosterone
Fluids
Diuretics
Type 2 Diabetes Mellitus
Medical problems
Renal Reabsorption
Pharmacology
Kidney
Genes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. / Guan, You Fei; Hao, Chuanming; Cha, Dae-Ryong; Rao, Reena; Lu, Wendell; Kohan, Donald E.; Magnuson, Mark A.; Redha, Reyadh; Zhang, Yahua; Breyer, Matthew D.

In: Nature Medicine, Vol. 11, No. 8, 01.08.2005, p. 861-866.

Research output: Contribution to journalArticle

Guan, YF, Hao, C, Cha, D-R, Rao, R, Lu, W, Kohan, DE, Magnuson, MA, Redha, R, Zhang, Y & Breyer, MD 2005, 'Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption', Nature Medicine, vol. 11, no. 8, pp. 861-866. https://doi.org/10.1038/nm1278
Guan, You Fei ; Hao, Chuanming ; Cha, Dae-Ryong ; Rao, Reena ; Lu, Wendell ; Kohan, Donald E. ; Magnuson, Mark A. ; Redha, Reyadh ; Zhang, Yahua ; Breyer, Matthew D. / Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. In: Nature Medicine. 2005 ; Vol. 11, No. 8. pp. 861-866.
@article{75d38380d26e46acaad24028d551d8a3,
title = "Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption",
abstract = "Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator- activated receptor-γ (PPARγ, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct-specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Ppargflox/flox mice. Deletion of collecting duct Pparg decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding the epithelial Na+ channel ENaCγ) expression through a PPARγ-dependent pathway. These studies identify Scnn1g as a PPARγ target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.",
author = "Guan, {You Fei} and Chuanming Hao and Dae-Ryong Cha and Reena Rao and Wendell Lu and Kohan, {Donald E.} and Magnuson, {Mark A.} and Reyadh Redha and Yahua Zhang and Breyer, {Matthew D.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1038/nm1278",
language = "English",
volume = "11",
pages = "861--866",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

AU - Guan, You Fei

AU - Hao, Chuanming

AU - Cha, Dae-Ryong

AU - Rao, Reena

AU - Lu, Wendell

AU - Kohan, Donald E.

AU - Magnuson, Mark A.

AU - Redha, Reyadh

AU - Zhang, Yahua

AU - Breyer, Matthew D.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator- activated receptor-γ (PPARγ, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct-specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Ppargflox/flox mice. Deletion of collecting duct Pparg decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding the epithelial Na+ channel ENaCγ) expression through a PPARγ-dependent pathway. These studies identify Scnn1g as a PPARγ target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.

AB - Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator- activated receptor-γ (PPARγ, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct-specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Ppargflox/flox mice. Deletion of collecting duct Pparg decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding the epithelial Na+ channel ENaCγ) expression through a PPARγ-dependent pathway. These studies identify Scnn1g as a PPARγ target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.

UR - http://www.scopus.com/inward/record.url?scp=23844472901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844472901&partnerID=8YFLogxK

U2 - 10.1038/nm1278

DO - 10.1038/nm1278

M3 - Article

C2 - 16007095

AN - SCOPUS:23844472901

VL - 11

SP - 861

EP - 866

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 8

ER -